Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: RockyBalboa who wrote (2168)	11/18/2008 10:33:55 AM
From: tuck	Read Replies (2) \| Respond to of 3661

I'm surprised the expectations were so high. It was a desperate act to buy this drug, even as cheaply as they got it, from Dove. When it failed P3 in back pain two years ago, the excuse was the placebo response was too high, masking the drug's effect. No one should be surprised by this failure, but what an obvious short candidate this was if you could borrow under $5 . . . Have fun with the grass; hope it works, but they have no cash or pipe, do they? So if you're lucky, they can be a useful shell company? Cheers, Tuck